Current role of diethylstilbestrol in the management of advanced prostate cancer

Authors

  • Pierre-Olivier Bosset,

    1. Urology Academic Department of la Pitié-Salpêtrière Hospital, Assistance Publique- Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris
    Search for more papers by this author
  • Laurence Albiges,

    1. Institut Gustave Roussy, Université Paris XI, Villejuif, France
    Search for more papers by this author
  • Thomas Seisen,

    1. Urology Academic Department of la Pitié-Salpêtrière Hospital, Assistance Publique- Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris
    Search for more papers by this author
  • Thibault de la Motte Rouge,

    1. Department of Medical Oncology, Centre de Lutte contre le Cancer (CLCC)
    Search for more papers by this author
  • Véronique Phé,

    1. Urology Academic Department of la Pitié-Salpêtrière Hospital, Assistance Publique- Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris
    Search for more papers by this author
  • Marc-Olivier Bitker,

    1. Urology Academic Department of la Pitié-Salpêtrière Hospital, Assistance Publique- Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris
    Search for more papers by this author
  • Morgan Rouprêt

    Corresponding author
    1. Urology Academic Department of la Pitié-Salpêtrière Hospital, Assistance Publique- Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris
    Search for more papers by this author

Morgan Rouprêt, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75013 Paris, France. e-mail: morgan.roupret@psl.aphp.fr

Abstract

What's known on the subject? and What does the study add?

Diethylstilbestrol (DES) has been found to have anti-tumour properties and clinical effectiveness in prostate cancer that is resistant to the first-line hormonal therapy.

This review found that low-dose DES has anti-tumour efficacy with limited cardiovascular side effects and should be considered for secondary hormone manoeuvres.

The aim of this review was to describe the most recent data from contemporary clinical trials of diethylstilbestrol (DES) to better determine its current role in advanced prostate cancer treatment as new hormonal therapies emerge. Relevant clinical studies using 1 mg of DES in castrate-resistant prostate cancer (CRPC) were identified from the literature, clinical trial databases, websites and conference abstracts. The efficacy and safety outcomes were summarized. DES in CRPC produced a biological response (change in PSA level) and improved the median survival of patients when used as a second-line hormone therapy after standard androgen deprivation with bicalutamide and LHRH analogues. These findings were for low doses of DES. The 1-mg dose is associated with a reduced toxicity, including fewer thromboembolic and cardiovascular events. Low-dose DES appears to be safe and effective for CRPC before initiating chemotherapy. The cost/efficiency ratio may encourage physicians to consider DES as a therapy option before chemotherapy in non-symptomatic CRPC.

Ancillary